About Managing Director

Jeannie Kim, BSc, MEM, MBA

Brings over 20 years of Life Science global corporate development and strategy leadership in enterprise transformations (ie. growth initiatives/turn-arounds) and building critical mass for pioneering and emerging technologies through strategy, optimizing portfolios and partnership ecosystems, as a consultant, advisor, and fractional executive (CBO/CBDO/COO/CSO/CMO).

With comprehensive background across traditional pharmaceuticals/biotech, med tech/techbio, and medical devices, she specializes in innovations that leverage their synergies and intersections to advance personalized medicine and/or improve access.

[eg. companion diagnostics (sequencing to POC in global health), molecular imaging/radioligands, robotic radioguided surgery/imaging (radiopharmaceutical-based surgical guidance), digital health applications for decentralized trials (interoperability), AI applications in discovery/translational research.]

Originally trained as an engineer, she began her career designing surgical instruments & dialysis devices for Baxter International and values creativity in both engagement and data-driven strategies, over retrofitted cookie-cutter methods for novel scientific/technological innovations.

Her corporate development background began on the buy-side with multinationals (Pharmacia/Pfizer, Philips Medical), with her first out-license/sell-side deal assignment was to secure a co-development partner for a drug-device program with zero external interest for over 2 years, earmarked for liquidation. A little over a year later, the program ultimately became a multinational partnership with Bayer and a Novartis platform acquisition valued close to $300M for Nektar.

Ms. Kim over the years successfully has closed over 50 transactions, >$5B in aggregate across (in/out) licensing, equity, and M&A -- in rare/orphan diseases, neurology, metabolic disorders, oncology, immunology, women’s health, infectious disease.

She’s held global corporate business development & strategy leadership roles and engagements with multinationals from Pfizer/Pharmacia/GD Searle (US, UK, MENEA), Johnson& Johnson, Philips Medical Systems, Pulmonary Unit of Nektar (now Novartis), Thermo Fisher Scientific – Clinical Sequencing, Biogen, GSK plc, and global health public-private partnerships, including PATH and Medicines360. She believes in compassionate leadership and enjoys leveraging her experience to drive growth for inspiring innovations, organizations, and people.

Ms.Kim holds a BSc in Biomedical/Mechanical Engineering, joint degree in Masters in Engineering Management and Masters in Business Administration from Northwestern University and Northwestern’s Kellogg School of Management, respectively, JD studies in Business Law/Animal (Environmental) Law at Lewis & Clark Northwestern School of Law. Stanford Medicine certification in Evaluations of AI applications in healthcare.

Member of Northwestern’s Alumni Admissions Council with strong interest in the arts, animal welfare, wildlife conservation, and poverty alleviation.